Publications by authors named "Manish B Patel"
Article Synopsis
- Maize is a vital cereal crop significantly impacted by climate change, necessitating the development of climate-smart varieties through the exploration of genetic diversity.
- Researchers screened 96 maize inbred lines for traits linked to yield and grain quality, examining them in two environments while employing SSR markers to assess genetic diversity and trait associations.
- Results showed positive correlations among nutritional content and yield traits, with genetic distance varied among lines, ultimately identifying distinct maize groups and specific genotypes for potential use in future breeding programs.
Article Synopsis
- * The process involved creating multi-parent yellow synthetic populations from elite lines, focusing on drought and waterlogging tolerance, and advancing through three breeding cycles based on the top-performing individuals.
- * The study found significant genetic gains in grain yield under drought conditions, with minimal impact on yield in optimal moisture scenarios, indicating that RC-GS can boost genetic progress while maintaining genetic diversity.
Background: Atherosclerosis, inflammation and coronary plaque destabilization are linked to each other. Infections due to various microbes may trigger Acute Coronary Syndrome (ACS) by systemic inflammation cascade.
Methods: We have evaluated the prevalence of Post Chikungunya Chronic Arthritis (PCCA) among 400 consecutive ACS patients (Case group) and compared with control group subjected to elective surgery by the prospective case-control observational study.
Introduction: Real-world comparative effectiveness, safety, and supportive care use of -paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).
Materials And Methods: Patients who received ≥ 1 cycle of first-line -paclitaxel plus carboplatin or gemcitabine plus platinum were identified from the Navigating Cancer database. Clinical effectiveness endpoints included overall survival (OS) and time to treatment discontinuation (TTD).
Introduction: Despite a clinically relevant, statistically significant survival benefit with -paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients with mPC using a nationally representative electronic medical records database to address this unmet need.
Methods: This retrospective analysis of the Navigating Cancer database compared outcomes among patients who received first-line -paclitaxel plus gemcitabine, FOLFIRINOX, or gemcitabine for mPC.
Background: We compared real-world treatment patterns, resource utilization, and cost of care for patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel + gemcitabine or FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin).
Methods: This was a retrospective study of inpatient and hospital-based outpatient data in the United States. Primary endpoints included median time to treatment discontinuation (TTD) and total cost of care per patient per month.
Background: Weekly (qw) nanoparticle albumin-bound (nab)-paclitaxel was approved for advanced non-small-cell lung cancer based on the results from a phase III trial in which nab-paclitaxel/carboplatin demonstrated a significantly greater response rate compared with paclitaxel/carboplatin every 3 weeks (q3w). Little information exists on relative real-world results.
Materials And Methods: The present retrospective study used data from a national electronic medical record database.
Effects of ethanol extract of Ficus bengalensis (bark) on inflammatory bowel disease.
Indian J Pharmacol
August 2010
Objective: The present study was designed to evaluate the effects of ethanol extract of Ficus bengalensis Linn. bark (AEFB) on inflammatory bowel disease (IBD).
Materials And Methods: Effects of AEFB were studied on 2,4,6-trinitrobenzenesulfonic acid (TNBS, 0.